Rekombinanter CTLA-4 (Tremelimumab Biosimilar) Antikörper

Produktnummer ABIN7200670

Dieser Anti-CTLA-4 (Tremelimumab Biosimilar) Antikörper ist ein Maus Monoklonal Antikörper zur Detektion von CTLA-4 (Tremelimumab Biosimilar) in FACS und in vivo. Geeignet für Human.

Kurzübersicht für Rekombinanter CTLA-4 (Tremelimumab Biosimilar) Antikörper (ABIN7200670)

Target: CTLA-4 (Tremelimumab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser CTLA-4 (Tremelimumab Biosimilar) Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), In vivo Studies (in vivo)

Güteklasse: Research Grade

Produktdetails anti-CTLA-4 (Tremelimumab Biosimilar) Antikörper

Verwendungszweck: Tremelimumab Biosimilar, Human CTLA-4 monoclonal antibody

Spezifität: The in vivo grade tremelimumab biosimilar specifically binds to the human protein receptor CD152 / CTLA4.

Produktmerkmale: What is Tremelimumab biosimilar research grade? Tremelimumab (formerly ticilimumab) is a fully human monoclonal antibody against CTLA-4 / CD152. It is an immune checkpoint blocker. Unlike Ipilimumab (another fully human anti-CTLA-4 / CD152 monoclonal antibody), which is an IgG1 isotype, tremelimumab is an IgG2 isotype.Tremelimumab Biosimilar uses the same protein sequences as the therapeutic antibody tremelimumab. Tremelimumab aims to stimulate an immune system attack on tumors. Cytotoxic T lymphocytes (CTLs) can recognize and destroy cancer cells. However, there is also an inhibitory mechanism (immune checkpoint) that interrupts this destruction. Tremelimumab turns off this inhibitory mechanism and allows CTLs to continue to destroy the cancer cells. This is immune checkpoint blockade. Tremelimumab binds to the protein CTLA-4 / CD152, which is expressed on the surface of activated T lymphocytes and inhibits the killing of cancer cells. Tremelimumab blocks the binding of the antigen-presenting cell ligands B7.1 and B7.2 to CTLA-4 / CD152, resulting in inhibition of B7-CTLA-4-mediated downregulation of T-cell activation, subsequently, B7.1 or B7.2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA-4-mediated inhibition.

Aufreinigung: Protein A or G affinity column

Reinheit: >95 % by reducing SDS-PAGE

Sterilität: 0.2 μm filtered

Endotoxin-Niveau: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: The anti-human CTLA-4 monoclonal antibody tremelimumab biosimilar (research grade) was produced in mammalian cells.

Isotyp: IgG2

Anwendungsinformationen

Applikationshinweise: ELISA, neutralization, in vivo functional assays such as bioanalytical PK and ADA assays, and those in vitro and in vivo assays for studying biological pathways affected by tremelimumab.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: > 3 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Konservierungsmittel: Without preservative

Lagerung: 4°C,-20 °C

Informationen zur Lagerung: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Haltbarkeit: 12 months

Details zu CTLA-4 (Tremelimumab Biosimilar)

Target: CTLA-4 (Tremelimumab Biosimilar)

Andere Bezeichnung: Tremelimumab Biosimilar

Substanzklasse: Biosimilar